(NYSE: TMO) Thermo Fisher Scientific's forecast annual revenue growth rate of 6.46% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.27%.
Thermo Fisher Scientific's revenue in 2026 is $43,736,000,000.On average, 29 Wall Street analysts forecast TMO's revenue for 2026 to be $17,761,598,489,225, with the lowest TMO revenue forecast at $16,962,091,739,673, and the highest TMO revenue forecast at $18,815,459,594,720. On average, 28 Wall Street analysts forecast TMO's revenue for 2027 to be $18,695,984,431,958, with the lowest TMO revenue forecast at $17,829,601,647,904, and the highest TMO revenue forecast at $20,127,056,428,689.
In 2028, TMO is forecast to generate $19,895,244,556,286 in revenue, with the lowest revenue forecast at $18,839,504,910,496 and the highest revenue forecast at $21,818,118,402,248.